Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Assura accepts £1.6bn merger offer from KKR, Stonepeak

(Sharecast News) - UK medical property Assura on Wednesday said it had agreed to a £1.61bn takeover offer from private investors KKR and Stonepeak Partners after rebuffing a lower bid from Primary Health Properties.

The US-based private equity offered 49.4p a share - a 33.5% premium to the closing price on February 13, a day before the first of five bids was disclosed.

Assura shareholders will get 48.56p a share in cash and a quarterly interim dividend of 0.84p each due to be paid on April 9.

"The cash offer from KKR and Stonepeak offers an attractive opportunity for Assura shareholders to crystallise value immediately," said Assura chief executive Jonathan Murphy.

Earlier on Wednesday, Assura rejected a £1.5bn merger proposal from Primary Health Properties, saying it "is not at a level that is sufficient to be recommended to shareholders".

Under the terms of the PHP Proposal, Assura shareholders would receive 0.3848 new PHP shares and 9.08 pence in cash.

In a statement, PHP said it was considering its options and "continues to believe that a combination of Assura and PHP, as set out in its announcement of 3 April would deliver significant strategic and financial benefits for shareholders of both companies".

"The board of PHP will continue its engagement with the Assura board, and its advisers, to explore a possible combination."

It added that it did not agree with the "assertion that the KKR and Stonepeak Cash Offer represents a superior proposal", claiming its offer allows Assura shareholders to benefit from "value accretion, synergies and the ongoing dividend growth that the board of PHP believes will result from a combination of both companies".

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.